Implementation of a novel non-invasive test for monitoring control in individuals with congenital adrenal hyperplasia

2018 ◽  
Author(s):  
Irina Bacila ◽  
Carlo L Acerini ◽  
Ruth E Krone ◽  
Leena Patel ◽  
Sabah Alvi ◽  
...  
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Adrenal Hyperplasia ◽  
Non Invasive ◽  
Invasive Test

scholarly journals 012 Non-invasive prenatal diagnosis of congenital adrenal hyperplasia

2012 ◽  
Vol 24 ◽  
pp. S44
Author(s):  
M.I. New ◽  
O. Lekarev ◽  
T. Yuen ◽  
D.Y.M. Lo
Keyword(s):  
Prenatal Diagnosis ◽  
Congenital Adrenal Hyperplasia ◽  
Adrenal Hyperplasia ◽  
Non Invasive

scholarly journals Assessment of Steroid Hormones in Both Saliva and Blood During a Phase 2 Clinical Trial for the Use of Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A1012-A1012
Author(s):  
Brian Keevil ◽  
Kyriakie Sarafoglou ◽  
David Moriarty ◽  
Michael Huang ◽  
Chris Barnes ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Congenital Adrenal Hyperplasia ◽  
Steroid Hormones ◽  
Steroid Hormone ◽  
Phase 2 ◽  
Adrenal Hyperplasia ◽  
Time Points ◽  
Non Invasive ◽  
17 Hydroxyprogesterone ◽  
Trial Setting

Abstract Background: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is an autosomal recessive disorder characterized by an inability to synthesize endogenous cortisol resulting in overproduction of 17-hydroxyprogesterone (17-OHP) and androgens such as androstenedione (A4). Serum-based methods to measure steroid hormones typically require clinic visits and are not amenable to frequent, serial measurements when patient daily glucocorticoid doses are adjusted. Reliable, non-invasive new methodologies that can easily be adopted in a clinical trial setting are needed to complement existing measures of disease control. Here we report on the correlation between salivary and serum steroid hormone data from a Phase 2 proof-of-concept study for tildacerfont, a second generation corticotropin-releasing factor-1 (CRF1) receptor antagonist, which previously showed an ability to reduce excess adrenocorticotropic hormone (ACTH), 17-OHP, and A4 concentrations. Methods: Subjects with CAH under evaluation for tildacerfont underwent concurrent salivary and serum concentration measurements of androstenedione (A4), 17-hydroxyprogesterone (17-OHP) and testosterone (T) at approximately 8 am every 2 weeks for up to 6 weeks. Both serum and saliva samples were measured using liquid chromatography-tandem mass spectrometry. Results: 25 subjects (16 females) with a median age of 31 years (range 19-67) participated; median body mass index (BMI) was 27.8 kg/m2 (22-62 kg/m2). The number of matched samples across time points were: n=106 (17-OHP), n=106 (A4) and n=98 (T). 17-OHP and A4 were well correlated between serum and salivary assessments, r=0.80 (p<0.001) and r=0.80 (p<0.001), respectively, using kendall rank tests. T measurements had a lower correlation, r=0.67 (p<0.001). Over the duration of treatment, correlations between saliva and serum for 17-OHP and A4 were generally stable with only small differences across sex and clinic visit. Correlations between saliva and serum for T showed a moderate degree variability in women and a high degree of variability in men across visits. While correlations were high for A4 and 17-OHP, the magnitude of change, as a percentage of baseline across time points, was less pronounced with saliva as compared to serum. Conclusions: The ability to employ salivary steroid hormone measurements in CAH patients was demonstrated in a clinical trial setting. These data show that the measurement of the hormones 17-OHP and A4 in saliva may offer a promising, non-invasive approach to more frequently assessing response to therapy in patients with CAH.

926: Dorsal Nerve Preservation in Modified Reduction Clitoroplasty in Congenital Adrenal Hyperplasia (CAH)

2007 ◽  
Vol 177 (4S) ◽  
pp. 307-307
Author(s):  
Ariella Hochsztein ◽  
Rebecca Baergen ◽  
Emily Loyd ◽  
Jie Chen ◽  
Diane Felsen ◽  
...  
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Adrenal Hyperplasia ◽  
Nerve Preservation ◽  
Dorsal Nerve

Abstract #106: Congenital Adrenal Hyperplasia Presenting with Giant Adrenal Myelolipomas

2017 ◽  
Vol 23 ◽  
pp. 4-5
Author(s):  
Tarandeep Kaur ◽  
Peter Dipasco ◽  
Leland Graves
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Adrenal Hyperplasia
Sign in / Sign up

Export Citation Format

Share Document